Novo Nordisk (NVO) said Wednesday that it has accepted the US Inflation Reduction Act's Maximum Fair Price, or MFP, for its semaglutide-based Ozempic, Rybelsus, and Wegovy products, in Medicare Part D.
The company said the prices will be effective as of January 2027.
Novo Nordisk did not disclose specific pricing details but said it would have had a "negative low single-digit impact on global sales growth" for the full year 2025 had it been implemented on Jan. 1, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.